Jarrod P. Holmes - Concepedia

Author

Jarrod P. Holmes

Brooke Army Medical Center

Also Known As

J. Holmes, J. P. Holmes, J.P. Holmes, Jarrod Holmes, Jarrod P Holmes, Jarrod P. Holmes, Jarrod P. Holmes, MD, FACP

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Brooke Army Medical Center The University of Texas MD Anderson Cancer Center Uniformed Services University of the Health Sciences Joint Base San Antonio Walter Reed Army Institute of Research

About

Jarrod P. Holmes is an author at Brooke Army Medical Center specializing in medicine, immunology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	412
2	Immunology	6	6	389
3	Pathology	4	4	109
4	Health Sciences	2	2	42
5	Autoimmunity	1	1	37

Jarrod P. Holmes

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients EA Mittendorf, Guy T. Clifton, Jarrod P. Holmes, Annals of Oncology VaccinationVaccinologyOncologyVaccine DevelopmentFinal Report	2014	240
Combined Clinical Trial Results of a HER2/<i>neu</i>(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 George E. Peoples, Jarrod P. Holmes, Matthew T. Hueman, Clinical Cancer Research	2008	179
Clinical trial results of the HER‐2/<i>neu</i> (E75) vaccine to prevent breast cancer recurrence in high‐risk patients Elizabeth A. Mittendorf, Guy T. Clifton, Jarrod P. Holmes, Cancer	2011	170
Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/<i>neu</i>Peptide (AE37) Vaccine Jarrod P. Holmes, Linda C. Benavides, Jeremy D. Gates, Journal of Clinical Oncology	2008	136
The Impact of HER2/<i>neu</i>Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Linda C. Benavides, Jeremy D. Gates, Mark G. Carmichael, Clinical Cancer Research	2009	116
Results of the first phase 1 clinical trial of the HER‐2/<i>neu</i> peptide (GP2) vaccine in disease‐free breast cancer patients Mark G. Carmichael, Linda C. Benavides, Jarrod P. Holmes, Cancer	2009	100
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer Guy T. Clifton, Diane F. Hale, Timothy J. Vreeland, Clinical Cancer Research	2020	88
Optimal dose and schedule of an HER‐2/<i>neu</i> (E75) peptide vaccine to prevent breast cancer recurrence Jarrod P. Holmes, Jeremy D. Gates, Linda C. Benavides, Cancer	2008	50
Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial Ritesh Patil, Guy T. Clifton, Jarrod P. Holmes, Journal of the American College of Surgeons	2009	49
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine Jarrod P. Holmes, Guy T. Clifton, Ritesh Patil, Cancer	2010	48

Page 1